Wednesday, September 17, 2025

#Influenza at the #human - #animal #interface - #Summary and #risk assessment, from 2 July to 25 August 2025 (#WHO, September 17 '25)

 


New human cases{1,2}: 

-- From 2 July to 25 August 2025, based on reporting date, the detection of influenza A(H5N1) in five humans and influenza A(H9N2) in two humans were reported officially.  


Circulation of influenza viruses with zoonotic potential in animals

- High pathogenicity avian influenza (HPAI) events in poultry and non-poultry animal species continue to be reported to the World Organisation for Animal Health (WOAH).{3} 

- The Food and Agriculture Organization of the United Nations (FAO) also provides a global update on avian influenza viruses with pandemic potential.{4} 


Risk assessment{5}: 

- Sustained human to human transmission has not been reported from these events. 

- Based on information available at the time of this risk assessment update, the overall public health risk from currently known influenza A viruses detected at the human-animal interface has not changed and remains low

- The occurrence of sustained human-to-human transmission of these viruses is currently considered unlikely

- Although human infections with viruses of animal origin are infrequent, they are not unexpected at the human-animal interface.  


IHR compliance

- All human infections caused by a new influenza subtype are required to be reported under the International Health Regulations (IHR, 2005).{6} 

- This includes any influenza A virus that has demonstrated the capacity to infect a human and its haemagglutinin (HA) gene (or protein) is not a mutated form of those, i.e. A(H1) or A(H3), circulating widely in the human population. 

- Information from these notifications is critical to inform risk assessments for influenza at the human-animal interface.  


Avian influenza viruses in humans 

- Current situation:  Since the last risk assessment of 1 July 2025, four laboratory-confirmed human cases of A(H5N1) infection were detected in Cambodia and notified to WHO. 

- One human case of influenza A(H5N1) detected in a person in India and included in the previous risk assessment of 1 July 2025 was reported to WHO. 


A(H5N1), Cambodia 



All cases above had exposure to sick or dead backyard poultry

Rapid response teams from the public health and animal health sectors have been deployed to investigate and respond to the outbreak.  

Fifteen human infections with A(H5N1) viruses have been confirmed in Cambodia in 2025 and seven of these have been fatal

All these cases in 2025 had exposure to domestic birds or their environments. 

In some cases, the domestic birds were reported to be sick or dead. 

Influenza A(H5N1) viruses continue to be detected in domestic birds in Cambodia in 2025, including in areas where human cases have been detected.{7} 

Where the information is available, the genetic sequence data from the viruses from the human cases closely matches that from recent local animal viruses and are identified as clade 2.3.2.1e viruses

From the information available thus far on these recent human cases, there is no indication of human-to-human transmission of the A(H5N1) viruses.  

According to reports received by WOAH, various influenza A(H5) subtypes continue to be detected in wild and domestic birds in Africa, the Americas, Asia and Europe. 

Infections in non-human mammals are also reported, including in marine and land mammals.{8} 

A list of bird and mammalian species affected by HPAI A(H5) viruses is maintained by FAO.{9}


Risk Assessment for avian influenza A(H5N1) viruses:  

1. What is the current global public health risk of additional human cases of infection with avian influenza A(H5N1) viruses?  

-- Most human cases so far have been infections in people exposed to A(H5) viruses, for example, through contact with infected poultry or contaminated environments, including live poultry markets, and occasionally infected mammals and contaminated environments. 

-- As long as the viruses continue to be detected in animals and related environments humans are exposed to, further human cases associated with such exposures are expected but unusual. 

-- The impact for public health if additional cases are detected is minimal

-- The current overall global public health risk of additional human cases is low

2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H5N1) viruses related to the events above?  

-- No sustained human-to-human transmission has been identified associated with the recent reported human infections with avian influenza A(H5N1) viruses. 

-- There has been no reported human-tohuman transmission of A(H5N1) viruses since 2007, although there may be gaps in investigations. 

-- In 2007 and the years prior, small clusters of A(H5) virus infections in humans were reported, including some involving health care workers, where limited human-to-human transmission could not be excluded; however, sustained human-to-human transmission was not reported.  

-- Current evidence suggests that influenza A(H5N1) viruses related to these events did not acquire the ability to efficiently transmit between people, therefore sustained human-to-human transmission is thus currently considered unlikely.  

3. What is the likelihood of international spread of avian influenza A(H5N1) viruses by travellers?  

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

-- If this were to occur, further communitylevel spread is considered unlikely as current evidence suggests these viruses have not acquired the ability to transmit easily among humans.  


A(H9N2), China

Since the last risk assessment of 1 July 2025, two human cases of infection with A(H9N2) influenza viruses were notified to WHO from China on 8 July 2025. 

The cases in children were detected in Guangdong and Hubei provinces, with onset of symptoms in May and June, respectively. 

Both cases had mild illness, were not hospitalized and recovered. 

The cases had a known history of exposure to backyard poultry or a live poultry market prior to the onset of symptoms. 

No further cases were detected among contacts of these cases.   


Risk Assessment for avian influenza A(H9N2):

1. What is the global public health risk of additional human cases of infection with avian influenza A(H9N2) viruses?

-- Most human cases follow exposure to the A(H9N2) virus through contact with infected poultry or contaminated environments. 

-- Most human infections of A(H9N2) to date have resulted in mild clinical illness. 

-- Since the virus is endemic in poultry in multiple countries in Africa and Asia{11}, further human cases associated with exposure to infected poultry are expected but remain unusual. 

-- The impact to public health if additional cases are detected is minimal

-- The overall global public health risk of additional human cases is low.  

2. What is the likelihood of sustained human-to-human transmission of avian influenza A(H9N2) viruses related to this event?

-- At the present time, no sustained human-to-human transmission has been identified associated with the recent reported human infections with A(H9N2) viruses. 

-- Current evidence suggests that influenza A(H9N2) viruses from these cases did not acquire the ability of sustained transmission among humans, therefore sustained human-to-human transmission is thus currently considered unlikely.   

3. What is the likelihood of international spread of avian influenza A(H9N2) virus by travellers?

-- Should infected individuals from affected areas travel internationally, their infection may be detected in another country during travel or after arrival. 

-- If this were to occur, further community level spread is considered unlikely as current evidence suggests the A(H9N2) virus subtype has not acquired the ability to transmit easily among humans.   


Overall risk management recommendations: Surveillance and investigations 

Due to the constantly evolving nature of influenza viruses, WHO continues to stress the importance of global strategic surveillance in animals and humans to detect virologic, epidemiologic and clinical changes associated with circulating influenza viruses that may affect human (or animal) health. Continued vigilance is needed within affected and neighbouring areas to detect infections in animals and humans. Close collaboration with the animal health and environment sectors is essential to understand the extent of the risk of human exposure and to prevent and control the spread of animal influenza. WHO has published guidance on surveillance for human infections with avian influenza A(H5) viruses. 

As the extent of influenza virus circulation in animals is not clear, epidemiologic and virologic surveillance and the follow-up of suspected human cases should continue systematically. Guidance on investigation of non-seasonal influenza and other emerging acute respiratory diseases has been published on the WHO website. 

Countries should increase avian influenza surveillance in domestic and wild birds, enhance surveillance for early detection in cattle populations in countries where HPAI is known to be circulating, include HPAI as a differential diagnosis in non-avian species, including cattle and other livestock populations, with high risk of exposure to HPAI viruses; monitor and investigate cases in non-avian species, including livestock, report cases of HPAI in all animal species, including unusual hosts, to WOAH and other international organizations, share genetic sequences of avian influenza viruses in publicly available databases, implement preventive and early response measures to break the HPAI transmission cycle among animals through movement restrictions of infected livestock holdings and strict biosecurity measures in all holdings, employ good production and hygiene practices when handing animal products, and protect persons in contact with suspected/infected animals.{10} More guidance can be found from WOAH and FAO. 

When there has been human exposure to a known outbreak of an influenza A virus in domestic poultry, wild birds or other animals – or when there has been an identified human case of infection with such a virus – enhanced surveillance in potentially exposed human populations becomes necessary. Enhanced surveillance should consider the health care seeking behaviour of the population, and could include a range of active and passive health care and/or communitybased approaches, including: enhanced surveillance in local influenza-like illness (ILI)/SARI systems, active screening in hospitals and of groups that may be at higher occupational risk of exposure, and inclusion of other sources such as traditional healers, private practitioners and private diagnostic laboratories. 

Vigilance for the emergence of novel influenza viruses with pandemic potential should be maintained at all times including during a non-influenza emergency. In the context of the cocirculation of SARS-CoV-2 and influenza viruses, WHO has updated and published practical guidance for integrated surveillance. 


Notifying WHO 

All human infections caused by a new subtype of influenza virus are notifiable under the International Health Regulations (IHR, 2005).{11} State Parties to the IHR (2005) are required to immediately notify WHO of any laboratory-confirmed512 case of a recent human infection caused by an influenza A virus with the potential to cause a pandemic{6,13}. Evidence of illness is not required for this report. 

WHO published the case definition for human infections with avian influenza A(H5) virus requiring notification under IHR (2005): https://www.who.int/teams/global-influenzaprogramme/avian-influenza/case-definitions


Virus sharing and risk assessment 

It is critical that these influenza viruses from animals or from humans are fully characterized in appropriate animal or human health influenza reference laboratories. Under WHO’s Pandemic Influenza Preparedness (PIP) Framework, Member States are expected to share influenza viruses with pandemic potential on a timely basis{14} with a WHO Collaborating Centre for influenza of GISRS. The viruses are used by the public health laboratories to assess the risk of pandemic influenza and to develop candidate vaccine viruses.  

The Tool for Influenza Pandemic Risk Assessment (TIPRA) provides an in-depth assessment of risk associated with some zoonotic influenza viruses – notably the likelihood of the virus gaining human-to-human transmissibility, and the impact should the virus gain such transmissibility. TIPRA maps relative risk amongst viruses assessed using multiple elements. The results of TIPRA complement those of the risk assessment provided here, and those of prior TIPRA analyses will be published at http://www.who.int/teams/global-influenza-programme/avian-influenza/toolfor-influenza-pandemic-risk-assessment-(tipra).  


Risk reduction 

Given the observed extent and frequency of avian influenza in poultry, wild birds and some wild and domestic mammals, the public should avoid contact with animals that are sick or dead from unknown causes, including wild animals, and should report dead birds and mammals or request their removal by contacting local wildlife or veterinary authorities.  

Eggs, poultry meat and other poultry food products should be properly cooked and properly handled during food preparation. Due to the potential health risks to consumers, raw milk should be avoided. WHO advises consuming pasteurized milk. If pasteurized milk isn’t available, heating raw milk until it boils makes it safer for consumption. 

WHO has published practical interim guidance to reduce the risk of infection in people exposed to avian influenza viruses. 


Trade and travellers 

WHO advises that travellers to countries with known outbreaks of animal influenza should avoid farms, contact with animals in live animal markets, entering areas where animals may be slaughtered, or contact with any surfaces that appear to be contaminated with animal excreta. Travelers should also wash their hands often with soap and water. All individuals should follow good food safety and hygiene practices.  

WHO does not advise special traveller screening at points of entry or restrictions with regards to the current situation of influenza viruses at the human-animal interface. For recommendations on safe trade in animals and related products from countries affected by these influenza viruses, refer to WOAH guidance.  


Links:  

-- WHO Human-Animal Interface web page https://www.who.int/teams/global-influenza-programme/avian-influenza 

-- WHO Influenza (Avian and other zoonotic) fact sheet https://www.who.int/news-room/fact-sheets/detail/influenza-(avian-and-other-zoonotic) 

-- WHO Protocol to investigate non-seasonal influenza and other emerging acute respiratory diseases https://www.who.int/publications/i/item/WHO-WHE-IHM-GIP-2018.2 

-- WHO Public health resource pack for countries experiencing outbreaks of influenza in animals:  https://www.who.int/publications/i/item/9789240076884 

-- Cumulative Number of Confirmed Human Cases of Avian Influenza A(H5N1) Reported to WHO  https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-a-h5n1-virus 

-- Avian Influenza A(H7N9) Information https://www.who.int/teams/global-influenza-programme/avian-influenza/avian-influenza-a-(h7n9)virus 

-- World Organisation of Animal Health (WOAH) web page: Avian Influenza  https://www.woah.org/en/home/ 

-- Food and Agriculture Organization of the United Nations (FAO) webpage: Avian Influenza https://www.fao.org/animal-health/avian-flu-qa/en/ 

-- OFFLU http://www.offlu.org/ 

____

{1} This summary and assessment covers information confirmed during this period and may include information received outside of this period. 

{2} For epidemiological and virological features of human infections with animal influenza viruses not reported in this assessment, see the reports on human cases of influenza at the human-animal interface published in the Weekly Epidemiological Record here.  

{3} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{4} Food and Agriculture Organization of the United Nations (FAO). Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential

{5} World Health Organization (2012). Rapid risk assessment of acute public health events. World Health Organization. Available at: https://iris.who.int/handle/10665/70810

{6} World Health Organization. Case definitions for the 4 diseases requiring notification to WHO in all circumstances under the International Health Regulations (2005). Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).  

{7} https://wahis.woah.org/#/in-event/5754/dashboard 

{8} World Organisation for Animal Health (WOAH). Avian influenza. Global situation. Available at: https://www.woah.org/en/disease/avian-influenza/#ui-id-2

{9} Food and Agriculture Organization of the United Nations. Global Avian Influenza Viruses with Zoonotic Potential situation update. Available at: https://www.fao.org/animal-health/situation-updates/global-aiv-withzoonotic-potential/bird-species-affected-by-h5nx-hpai/en

{10} World Organisation for Animal Health. Statement on High Pathogenicity Avian Influenza in Cattle, 6 December 2024. Available at: https://www.woah.org/en/high-pathogenicity-avian-influenza-hpai-in-cattle/

{11} World Health Organization. Case definitions for the four diseases requiring notification in all circumstances under the International Health Regulations (2005).    

{12} World Health Organization. Manual for the laboratory diagnosis and virological surveillance of influenza (2011). Available at: https://apps.who.int/iris/handle/10665/44518 

{13} World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits, 2nd edition. Available at: https://iris.who.int/handle/10665/341850 

{14} World Health Organization. Operational guidance on sharing influenza viruses with human pandemic potential (IVPP) under the Pandemic Influenza Preparedness (PIP) Framework (2017). Available at: https://apps.who.int/iris/handle/10665/25940 

Source: World Health Organization, https://www.who.int/publications/m/item/influenza-at-the-human-animal-interface-summary-and-assessment--25-august-2025

____

#Ai and infectious disease #diagnostics: state of the art and future #perspectives

 


Summary

Artificial intelligence (AI) is reshaping infectious disease diagnostics by supporting clinical decision making, optimising laboratory and clinical workflows, and enabling real-time disease surveillance. AI approaches improve pathogen detection, antimicrobial stewardship, and treatment monitoring, enhancing diagnostic accuracy, efficiency, and scalability. The role of AI in combating antimicrobial resistance is particularly significant, enabling rapid pathogen identification and personalised treatment. Despite progress over the past two decades, widespread AI adoption in infectious disease diagnostics faces challenges. In high-income countries, fragmented data ecosystems, incomplete datasets, and algorithmic bias hinder clinical integration. Meanwhile, low-income and middle-income countries contend with limited digital infrastructure, unstandardised data, and financial constraints, exacerbating disparities in diagnostic access. Further barriers include concerns over interoperability, data privacy, cybersecurity, and the regulation of AI implementation. This paper examines the role of AI in infectious disease diagnostics, highlighting both opportunities and limitations. It underscores the need for coordinated investments in digital infrastructure, harmonised data-sharing frameworks, and clinician engagement to support equitable, sustainable adoption. Addressing these challenges will enable health-care systems to harness the potential of AI to improve infectious disease detection, prevention, and management of infectious diseases, thereby strengthening global health resilience.

Source: Lancet Infectious Diseases, https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(25)00354-8/abstract?rss=yes

____

Tuesday, September 16, 2025

Long Term #Risk #Assessment: #COVID19, 5 September 2025 (#WHO, summary)



Overall global risk and confidence*

Overall risk:  Global  - Moderate   

Confidence in available information: Global - Low 


Overall risk statement

As of mid-2025, the global public health risk from COVID-19 has changed from high to moderate, with declining deaths and hospitalizations since 2022 due to high population immunity, improved clinical management, and similar virulence

Most SARSCoV-2 variants now belong to the JN.1 Omicron sublineages, which show immune escape but do not result in increased disease severity. 

Nonetheless, surveillance gaps, reduced genomic sequencing and sharing of sequence information, and limited reporting, especially from low- and middle-income countries, undermine accurate risk assessment

SARS-CoV-2 continues to circulate widely, as indicated by sentinel testing and wastewater surveillance, often co-circulating with influenza and RSV

PostCOVID-19 condition is estimated to affect around 6% of symptomatic cases, with reduced risk in vaccinated individuals

WHO encourages integration of COVID-19 monitoring into broader respiratory disease surveillance systems and recommends ongoing vaccination of high-risk populations

While available vaccines remain effective against severe disease and death even in light of variant emergence, global vaccine uptake among high-risk groups was low in 2024, raising concerns amid continued virus evolution. 

Overall, while the direct impact of COVID-19 has lessened, ongoing circulation and virus evolution – both in human populations and established animal reservoirs, low vaccine uptake, and insufficient burden and genomic surveillance data contribute to uncertainty, requiring continued vigilance. 

{*} Confidence refers to the level of confidence in the data/information or the quality of the evidence available at the time the RRA is conducted. Poor quality information may increase the overall perceived risk due to the incertitude in the assessment. 

(...)

Supporting information

Virus origins

The Scientific Advisory Group for the Origins of Novel Pathogens (SAGO) is composed of independent scientific experts whose role is to advise WHO on technical and scientific considerations regarding emerging and reemerging pathogens, including SARS-CoV-2. 

SAGO published its independent assessment of SARS-CoV-2 origins on 27 June 2025. 

While available information is insufficient to definitively conclude the origins of SARS-CoV-2, the report includes two main hypotheses:  

-- introduction from a natural zoonotic source(s) as a spillover event(s) either directly to humans from wild animals or through an intermediate host, or 

-- an accidental laboratory-related event, which may have involved exposure to the virus during field research or a breach in laboratory biosafety procedures.  

SAGO has also developed a global framework to define and guide studies on the origins of emerging and reemerging pathogens of epidemic and pandemic potential, published in February 2025 and outlining a structured approach for investigating the origins of a novel pathogen. 


Virus evolution and variants

Omicron, the last designated variant of concern (VOC), has accounted for 97% of all submitted sequences since January 2022. Omicron has diversified considerably, giving rise to more than 2800 descendent lineages

All Omicron descendent lineages share similar phenotypic characteristics, namely higher transmissibility due to immune escape properties and lower apparent disease severity as compared to pre-Omicron variants. 

WHO continuously updates its tracking system and definitions for variants of SARS-CoV-2 to reflect the current global variant landscape. 

At present, WHO is monitoring one designated variant of interest (VOI), JN.1, and six designated variants under monitoring (VUMs): KP.3, KP.3.1.1, XEC, LP.8.1, NB.1.8.1 and XFG, all descendent lineages of JN.1. 

Between epidemiological weeks ending on 8 June 2025 and 29 June 2025  the VOI JN.1 decreased in proportion from 9.4% to 6.6%. 

During the same period, the VUM XFG increased from 23.3% to 39.1%, NB.1.8.1 increased from 28.7% to 35.5%, LP.8.1 decreased from 25.7 to 11.1, XEC decreased from 4.5% to 2.8%, KP.3 decreased from 0.7% to 0.4%, and KP.3.1.1 remained stable at 2.1%.  

Risk evaluations on the current VOI and VUMs indicate they do not pose additional public health risks as compared to other currently circulating SARS-CoV-2 lineages. 

With declining prevalence of VOIs, and VUMs increasingly unable to meet the VOI definition, WHO, on 29 November 2024, began conducting risk evaluations for VUM designations in addition to VOI designations. 

With declining prevalence of VOIs, and VUMs increasingly unable to meet the VOI definition, WHO, on 29 November 2024, began conducting risk evaluations for VUM designations in addition to VOI designations. 

Despite advances in sequencing capacity made during the pandemic, low, unrepresentative levels of genomic sequencing and sharing pose significant challenges to the assessment of the SARS-CoV-2 variant landscape. 

84% of WHO MS had capacity to sequence for SARS-CoV-2 and 94% had access to timely sequencing either internally or via international reference laboratories as of 31 December 2023. 

Between January and June 2025, a total of 88 903 sequences were shared globally by 91 countries. This marks a substantial decline compared to 462 676 sequences shared by 146 countries during the same period in 2024. While a decline in SARS-CoV-2 genomic sequencing is expected compared to the early pandemic years, the current low volume of sequences also reflects limited geographic representation—primarily from high income countries – with significant delays in sequencing and data sharing from the time of sample collection. 

Representative levels of genomic sequencing and sharing in a timely manner are essential for adequate, robust monitoring of existing SARS-CoV-2 variants and early detection and rapid assessment of emerging ones. 

WHO urges MS to maintain public reporting and publishing of genetic sequences with relevant meta-data. 

The Technical Advisory Group on Virus Evolution (TAG-VE) continues to meet as needed to assess available evidence on circulating SARS-CoV-2 variants. 

Previously specific to SARS-CoV-2, TAG-VE now has broadened its terms of reference to include other viruses, including monkeypox virus (MPXV) and Middle East respiratory syndrome coronavirus (MERS-CoV). 

Complementing the work of TAG-VE, the Technical Advisory Group on COVID19 Vaccine Composition (TAG-CO-VAC) also continues to meet regularly to assess the impact of changing variant circulation in the context of determining COVID-19 vaccine composition recommendations, as further described in below vaccine-related sections. 

(...)

Mortality

As of 29 June 2025, over seven million confirmed deaths had been reported globally to WHO. 

The number of weekly reported COVID-19-related deaths has been steadily declining, now consistently below 2000 since February 2024, a level comparable to March 2020. 

This is a significant decrease compared to previous periods, such as the 10 000 average deaths reported per week during the first half of 2023 and the over 35 000 during the first half of 2022. 

Similar to case reporting, the weekly average number of countries reporting death data has declined significantly from 173 countries in the first half of 2022 to 114 and 76 in the same periods of 2023 and 2024, respectively.   

In the first half of 2025 (as of 29 June), over 16 600 deaths were reported from 42 countries, averaging 640 deaths per week across 40 countries.

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/covid-19-global-risk-assessment-v8

____

#Germany - High pathogenicity avian #influenza #H5N1 viruses (#poultry) (Inf. with) - Follow up report 1



Ducks for fattening (1800), geese for fattening (100) in Mecklenburg-Vorpommern Region.

Laying hens (150). ducks for fattening (2800), geese for fattening (2900) in Mecklenburg-Vorpommern Region.

Source: WOAH, https://wahis.woah.org/#/in-review/6780

____

#DRC: #Ebola #Outbreak, Kasai Province Situation #Report #2, September 15, 2025 (ReliefWeb)

 


FAST FACTS

On September 4, the DRC Ministry of Health officially declared an outbreak of Ebola virus disease (EVD) in the Bulape and Mweka health zones in Kasai province.

According the the World Health Organization (WHO), as of September 15 there are 81 suspected cases and 28 deaths, including four nurses. However, data reporting has been challenging, with conflicting statistics reports being circulated by various health authorities.

Kasai is extremely isolated, sometimes requiring multiple days of driving from Kinshasa to Tshikapa, the provincial capital, during the rainy season. Very few air routes reach the province, though an airstrip in Bulape is being established.

Significant gaps exist in the response to EVD, including adequate case management capacity, blood supplies, IPC/WASH support, and more.


OUR RESPONSE

International Medical Corps has been responding in the DRC since 1999, and currently has offices in Goma and Kinshasa.

Our Rapid Response Team (RRT) has deployed to Kasai, with staff on the ground assessing and planning our response.

Through our US government-funded LEARN project, we are preparing to conduct training covering topics including case management and IPC.

Procurement of medical supplies, including personal protective equipment, has begun and will be used both as training materials and in response to EVD.

International Medical Corps will lead working groups on case management at the national and provincial level.

Source: ReliefWeb, https://reliefweb.int/report/democratic-republic-congo/dr-congo-ebola-outbreak-kasai-province-situation-report-2-september-15-2025

____

High-throughput neutralization measurements correlate strongly with evolutionary success of #human #influenza strains

 


Abstract

Human influenza viruses rapidly acquire mutations in their hemagglutinin (HA) protein that erode neutralization by antibodies from prior exposures. Here, we use a sequencing-based assay to measure neutralization titers for 78 recent H3N2 HA strains against a large set of children and adult sera, measuring ~10,000 total titers. There is substantial person-to-person heterogeneity in the titers against different viral strains, both within and across age cohorts. The growth rates of H3N2 strains in the human population in 2023 are highly correlated with the fraction of sera with low titers against each strain. Notably, strain growth rates are less correlated with neutralization titers against pools of human sera, demonstrating the importance of population heterogeneity in shaping viral evolution. Overall, these results suggest that high-throughput neutralization measurements of human sera against many different viral strains can help explain the evolution of human influenza.


Competing Interest Statement

JDB is on the scientific advisory boards of Apriori Bio, Invivyd, Aerium Therapeutics, and the Vaccine Company. JDB consults for GlaxoSmithKline and Pfizer. JDB and ANL receive royalty payments as inventors on Fred Hutch licensed patents related to incorporating barcodes into the influenza genome and viral deep mutational scanning. SEH is a co-inventor on patents that describe the use of nucleoside-modified mRNA as a vaccine platform. SEH reports receiving consulting fees from Sanofi, Pfizer, Lumen, Novavax, and Merck.


Funder Information Declared

National Institute of Allergy and Infectious Diseases, 75N93021C00015, T32AI083203, R01AI165821

Howard Hughes Medical Institute

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.03.04.641544v2

____

#Gaza: Top independent #rights #probe alleges #Israel committed #genocide

 


16 September 2025 

Senior independent rights investigators appointed by the Human Rights Council alleged on Tuesday that Israel’s actions in Gaza constitute genocide, a charge flatly rejected by Tel Aviv.

In a new report published against the backdrop of intensifying Israeli military operations in Gaza City, the UN Independent International Commission of Inquiry on the Occupied Palestinian Territory, including East Jerusalem, and Israel, urged Israel and all countries to fulfil their obligations under international law “to end the genocide” and punish those responsible.

“The Commission finds that Israel is responsible for the commission of genocide in Gaza,” insisted Navi Pillay, Chair of the Commission. “It is clear that there is an intent to destroy the Palestinians in Gaza through acts that meet the criteria set forth in the Genocide Convention.”

At a press conference in Geneva, the panel’s members - who are not UN staff but instead appointed by the Human Rights Council’s 47 Member States - explained that their investigations into the war in Gaza beginning with Hamas-led terror attacks in Israel on 7 October 2023 had led to the conclusion that Israeli authorities and security forces “committed four of the five genocidal acts defined by the 1948 Convention on the Prevention and Punishment of the Crime of Genocide”.

These acts are:

-- killing,

-- causing serious bodily or mental harm,

-- deliberately inflicting conditions of life calculated to bring about the destruction of the Palestinians, and

-- imposing measures intended to prevent births.

Ms. Pillay maintained that responsibility for the atrocity crimes “lies with Israeli authorities at the highest echelons”, amid “explicit statements” denigrating Palestinians by Israeli civilian and military authorities.

The Commission also analysed conduct of Israeli authorities and the Israeli security forces in Gaza, “including imposing starvation and inhumane conditions of life for Palestinians in Gaza…genocidal intent was the only reasonable inference that could be concluded from the nature of their operations”, the panel said.


Methodical examination

The Commission’s assertion follows its review of Israeli military operations in Gaza, “including killing and seriously harming unprecedented numbers of Palestinians” and the imposition of a “total siege, including blocking humanitarian aid leading to starvation”, it said.

According to the UN aid coordination wing, OCHA, nearly one million people remain in Gaza City, famine has been confirmed there, and residents face daily bombardment and “compromised access to means of survival after the Israeli military placed the entire city under a displacement order”.

For its latest report, the panel also examined what it called the “systematic destruction” of healthcare and education in Gaza and “systematic” acts of sexual and gender-based violence against Palestinians. 


Justice call

In addition, the Commission of Inquiry reviewed the alleged “direct targeting” of children and Israel’s “disregarding [of] the orders of the International Court of Justice, which issued an order in March 2024 that Israel should take ‘all necessary and effective measures to ensure…the unhindered provision at scale by all concerned of urgently needed basic services and humanitarian assistance to Palestinians throughout Gaza’”.

“The international community cannot stay silent on the genocidal campaign launched by Israel against the Palestinian people in Gaza,” said Ms. Pillay.

“When clear signs and evidence of genocide emerge, the absence of action to stop it amounts to complicity,” she added.

“All States are under a legal obligation to use all means that are reasonably available to them to stop the genocide in Gaza.”


Qatari dimension

In a related development on Tuesday, the Human Rights Council shuffled its schedule to make way for an urgent debate on last week’s Israeli strike on Hamas’s political leadership in Qatar.

The strike targeted a neighbourhood of the Qatari capital, Doha, reportedly killing six people including five members of Hamas and prompting widespread condemnation including from the Security Council and Secretary-General.

In a statement, AntĂ³nio Guterres spoke out against what he called a “flagrant violation” of Qatari sovereignty and territorial integrity.

And at a Security Council meeting called in response to the strike, the UN’s political affairs chief told ambassadors the attack in violation of Qatar’s sovereignty was a serious threat to regional peace and security. It also undermined international mediation efforts to end the war in Gaza and return the hostages, said Rosemary DiCarlo.

Source: United Nations, https://news.un.org/en/story/2025/09/1165856

____

Monday, September 15, 2025

Effect of Seasonal #Influenza #Vaccines on Avian Influenza #H5N1 Clade 2.3.4.4b Virus #Infection in #Ferrets

 


Abstract

Highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b viruses have infected >1,000 herds of dairy cattle and hundreds of poultry flocks in the United States since the beginning of 2024. Seventy human cases have been reported during that period, mainly through occupational exposure. Although prior influenza A(H1N1)pdm09 virus infection has been shown to confer protection against influenza A(H5N1) clade 2.3.4.4b virus infection in the ferret model, it remains unclear if influenza vaccines, known to elicit a less potent and narrower cross-reactive immune response, can achieve a similar effect. In this article, we demonstrate that immunization with commercially available human seasonal influenza vaccines also confers partial protection against disease caused by H5N1 clade 2.3.4.4b virus in ferrets, which is partially associated with the presence of cross-reactive antibodies targeting H5N1 virus antigens.

Source: US Centers for Disease Control and Prevention, https://wwwnc.cdc.gov/eid/article/31/10/25-0668_article

____

Avian #influenza: First #global #dialogue targets the rising #pandemic #threat

 


09/09/2025 - Foz do Iguaçu, Brazil 

In an unprecedented response to the rapid global spread of high pathogenicity avian influenza (HPAI), stakeholders and experts from across the poultry sector, public health, science, and policy spheres have convened in Brazil in a landmark meeting

This first-ever global multisectoral dialogue aims to forge coordinated defense against the escalating threat to animal and human health and agricultural livelihoods.

Avian influenza, commonly known as bird flu, is a highly contagious viral disease that primarily infects birds. The virus belongs to the Type A influenza family, which is known for its ability to mutate and change rapidly.

Since 2020, HPAI has expanded rapidly across continents, devastating poultry flocks, impacting biodiversity, trade and food security, and raising concerns over its potential to spark a human pandemic. The currently circulating avian influenza panzootic is now widespread, and represents one of the most serious pandemic threats, experts warn. Avian influenza has spread to 83 mammal species including dairy cattle and wildlife, and poses a rapidly evolving risk.

“Avian influenza is no longer a sporadic threat; it’s becoming a global challenge,” said Beth Bechdol, FAO Deputy Director-General. “No single country or sector can tackle this threat in isolation—and failure is not an option. Practical, science-based collaboration like this is essential to protect our agrifood systems, livelihoods, and public health,” she added.

Organized by the Food and Agriculture Organization of the United Nations (FAO) in partnership with the Brazilian Ministry of Agriculture and Livestock, the event “Tackling high pathogenicity avian influenza together - Global science, policy and private sector dialogue” brings together around 500 experts and decision-makers to galvanize multisectoral collaboration and investment. Representatives from the private sector, including industry associations involved in the production of poultry and the provision of animal health services are also joining government and scientific leaders for the first time in this type of global dialogue—providing an opportunity to better understand private sector’s challenges, recognize its ongoing efforts, and highlight the solutions it is already implementing to tackle the threat posed by avian influenza.

Experts from Asia, Africa, Europe, and the Americas – many of whom are members of FAO and World Organization for Animal Health (WOAH) OFFLU Network of Expertise on Animal Influenza – are also participating in the dialogue.

“Addressing avian influenza requires a collective effort that unites countries, productive sectors, the scientific community, and international organizations. This challenge must be met with full transparency, as only in this way can we build trust and safeguard global food security,” said Carlos Favaro, Brazil’s Minister of Agriculture and Livestock. “I would like to emphasize that this year, when avian influenza was detected on a commercial farm, Brazil demonstrated a decisive difference. Our swift and effective response highlighted the strength and credibility of Brazil’s sanitary system.”


Priority themes

The event seeks to build on the Global Strategy for the Prevention and Control of HPAI, recently launched by FAO in collaboration with WOAH. This strategy aims to support the development and implementation of national and regional action plans while strengthening global efforts to reduce transboundary and pandemic risks.

The three-day event focuses on:

-- Identifying effective HPAI prevention and control strategies—particularly in low-income countries and informal backyard poultry systems.

-- Promoting early warning systems, vaccination strategies, and biosecurity measures.

-- Enhancing multisectoral coordination based on the One Health approach.

-- Sharing innovative, field-ready solutions for diagnostics, surveillance, and outbreak response.

Thanawat Tiensin, Chief Veterinarian of FAO and Director of the Animal Production and Health Division summarized FAO’s approach in his remarks: “Improved surveillance, biosecurity, and vaccination when appropriate, combined with rapid disease control are keys to controlling this disease. At the same time, the sustainable transformation of poultry production offers new approaches and safeguards to prevent losses from poultry diseases. It will take a holistic approach and partnering with the private sector to effectively reduce the risk of avian influenza for generations to come.”

“The debate around Avian Influenza is a matter of international cooperation and requires joint efforts from all nations,” said Ricardo Santin, president of the Brazilian Association of Animal Protein and of the International Poultry Council. “It is an issue with a direct impact on trade flows and, consequently, on inflation and on global food security. These are sensitive matters that must be guided by knowledge and science, and that call for a revision of concepts and paradigms.”

(...)


____

Sunday, September 14, 2025

Patio in Capri, Konstantin Gorbatov (1925)

 


Public Domain.

Source: WikiArt, https://www.wikiart.org/en/konstantin-ivanovich-gorbatov/patio-in-capri-1925

____

#H3N2 #influenza virus #tropism shifts to glycan #receptors on tracheal ciliated cells

 


Abstract

Human H3N2 influenza viruses, introduced during the 1968 pandemic, have evolved to recognize human-type sialic acid-containing receptors (Neu5Acα2-6Gal) extended with at least three LacNAc (Galβ1-4GlcNAc) repeats. To investigate this restriction in the context of virus attachment to the airway epithelium, we comprehensively analyzed the glycome of human nasal and tracheal epithelial cells. Using a synthetic N-glycan library that reflects the structural diversity of the human airway glycome, we found that only bi-antennary N-glycans with extended human-type receptors on at least one branch serve as receptors for the recent H3 hemagglutinins (HAs). Such receptors are found on tracheal epithelium but are deficient in nasal epithelium. Immunofluorescence analysis on human trachea reveals that recent H3 HAs preferentially attach to ciliated cells, consistent with single-cell RNA sequencing analysis indicating that these cells express glycosyltransferases that produce extended glycan chains. These findings suggest that H3N2 viruses have developed a tropism for tracheal ciliated cells.


Competing Interest Statement

The authors have declared no competing interest.


Funder Information Declared

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, AI 114730, Contract No. 75N93021C00015

The Wellcome Trust, Grant 082098

Source: BioRxIV, https://www.biorxiv.org/content/10.1101/2025.09.12.675939v1

____

Saturday, September 13, 2025

Shifting tides: increased #severity despite fewer visits for #infant respiratory #infections across two consecutive post-pandemic winters in Northern #Italy

 


Abstract

This study compares infant (0–24 months) respiratory infection presentations to a Northern Italian paediatric emergency department across two post-pandemic winters (2022–2023 vs 2023–2024). Despite an approximate 44% reduction in visits in 2023–2024 (N=176 in 2023–2024 vs N=317 in 2022–2023), infants in the 2023–2024 season experienced significantly higher proportions of ventilatory support (51.1% vs 32.8%, p<0.001) and intensive care unit admission (15.9% vs 1.9%, p<0.001) than those presenting in 2022–2023, with a non-significant trend towards higher hospitalisation (88.1% vs 81.7%, p=0.052). Respiratory syncytial virus re-emerged as the dominant pathogen (43.2% vs 27.7%, p<0.001) in 2023–2024, alongside increased human metapneumovirus and influenza A H1N1. These findings highlight a concerning shift towards increased severity, underscoring the need for ongoing surveillance.

Source: BMJ Paediatric Open, https://bmjpaedsopen.bmj.com/content/9/1/e003695

____

History of Mass Transportation: The FS Class E.402 Electric Locomotive

 


By Bahnfrend - Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=18053425

Source: Wikipedia, https://en.wikipedia.org/wiki/FS_Class_E.402

____

#Coronavirus Disease Research #References (by AMEDEO, September 13 '25)

 


    Am J Respir Crit Care Med

  1. GORDHAN BG, Sewcharran A, Waja Z, Martinson N, et al
    Oral Rinse as an Alternative Diagnostic Specimen for Detection of Tuberculosis.
    Am J Respir Crit Care Med. 2025 Sep 12. doi: 10.1164/rccm.202503-0723.
    PubMed        

  2. CRESCIOLI E, Klitgaard TL, Riis JO, Weinreich UM, et al
    Oxygenation Targets and Long-Term Cognitive and Pulmonary Functions in Hypoxemic Respiratory Failure.
    Am J Respir Crit Care Med. 2025 Sep 8. doi: 10.1164/rccm.202412-2499.
    PubMed         Abstract available


    Clin Infect Dis

  3. NADIG N, Bhimraj A, Cawcutt K, Chiotos K, et al
    2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Abatacept.
    Clin Infect Dis. 2025 Sep 9:ciaf354. doi: 10.1093.
    PubMed         Abstract available


    Infect Control Hosp Epidemiol

  4. WILLIAMS V, Volpentesta K, Avaness M, Chan C, et al
    Risk of viral respiratory infection associated with shared washroom between adjoining rooms: a test-negative study.
    Infect Control Hosp Epidemiol. 2025 Sep 10:1-3. doi: 10.1017/ice.2025.10262.
    PubMed         Abstract available

  5. MITCHELL R, Lee D, Bartoszko J, Lybeck C, et al
    Trends in healthcare-associated infections and antimicrobial-resistant organisms among adults in Canadian acute care hospitals: findings from four point prevalence surveys, 2002 to 2024.
    Infect Control Hosp Epidemiol. 2025 Sep 10:1-8. doi: 10.1017/ice.2025.10259.
    PubMed         Abstract available

  6. SILVA A, Bartoszko JJ, Cayen J, Choi KB, et al
    An interrupted time-series analysis assessing the association of the COVID-19 pandemic on healthcare-associated infections and antimicrobial-resistant organisms in Canadian acute care hospitals, 2018-2022.
    Infect Control Hosp Epidemiol. 2025 Sep 10:1-5. doi: 10.1017/ice.2025.10247.
    PubMed        

  7. WILLIAMS V, Schwartz KL, Brown K, Muller M, et al
    Risk mitigation of shared room ventilation and filtration on SARS-CoV-2 transmission: a multicenter test-negative study.
    Infect Control Hosp Epidemiol. 2025 Sep 10:1-7. doi: 10.1017/ice.2025.10256.
    PubMed         Abstract available


    Int J Infect Dis

  8. PASQUINI Z, Toschi A, Gibertoni D, Amicucci A, et al
    Risk Factors for Persisting SARS-CoV-2 Infection in Patients with B-Cell Malignancies in the Omicron Era: A Multicenter Cohort Study.
    Int J Infect Dis. 2025 Sep 8:108053. doi: 10.1016/j.ijid.2025.108053.
    PubMed         Abstract available

  9. ROWE SL, Sullivan SG, Koerber JJ, Munoz FM, et al
    Adverse events associated with COVID-19 vaccination or diagnosis among pregnant and non-pregnant women in the United States, 2021-2022.
    Int J Infect Dis. 2025 Sep 5:108050. doi: 10.1016/j.ijid.2025.108050.
    PubMed         Abstract available


    J Med Virol

  10. GONZALEZ-VAZQUEZ LD, Iglesias-Rivas P, Ferreiro D, Arenas M, et al
    Heterogeneous Evolution Among SARS-CoV-2 Genes and Variants of Concern.
    J Med Virol. 2025;97:e70604.
    PubMed         Abstract available


    J Virol

  11. KASLE G, Sharma M, Kumar S, Das P, et al
    Phenylbutyrate restricts murine beta-coronavirus infectivity and limits virus-induced demyelination in vivo.
    J Virol. 2025 Sep 8:e0081925. doi: 10.1128/jvi.00819.
    PubMed         Abstract available

  12. JIAO Z, Li J, Wang P, Yan Y, et al
    Mutations in feline infectious peritonitis virus nonstructural protein 14/16 methyltransferase attenuate the pathogenicity of the virus in cats.
    J Virol. 2025 Sep 9:e0083925. doi: 10.1128/jvi.00839.
    PubMed         Abstract available

  13. LIZCANO-PERRET B, Wavreil F, Veinstein M, Duflos C, et al
    The leader proteins of Theiler's virus and Boone cardiovirus use a combination of short linear motifs (SLiMs) to target RSK kinases to the nuclear pore complex.
    J Virol. 2025 Sep 10:e0127525. doi: 10.1128/jvi.01275.
    PubMed         Abstract available

  14. WESTON S, Baracco L, Taylor L, Scott AJ, et al
    The mammalian SKI complex is a broad-spectrum antiviral drug target that upregulates cellular cholesterol to inhibit viral replication.
    J Virol. 2025 Sep 10:e0132325. doi: 10.1128/jvi.01323.
    PubMed         Abstract available


    JAMA

  15. RUDMAN SPERGEL AK, Callendret B, Kostanyan L
    Influenza and COVID-19 Multicomponent Vaccine in Adults-Reply.
    JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12225.
    PubMed        

  16. LIU Z, Zhang L, Jiang M
    Influenza and COVID-19 Multicomponent Vaccine in Adults.
    JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12222.
    PubMed        


    Lancet Infect Dis

  17. WILHELM F, Cadamuro J, Mink S
    Autoantibodies in long COVID: a systematic review.
    Lancet Infect Dis. 2025 Sep 8:S1473-3099(25)00411.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, September 13 '25)

 


    Antiviral Res

  1. ICHIKAWA T, Tamura T, Nao N, Suzuki H, et al
    Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.
    Antiviral Res. 2025;242:106264.
    PubMed         Abstract available

  2. BI W, Zhu T, Xu Y, Chen Y, et al
    An engineered chimeric ACE2-HR2 peptide exhibits potent and broad-spectrum activity against SARS-CoV-2 variants.
    Antiviral Res. 2025;242:106265.
    PubMed         Abstract available

  3. TERATAKE Y, Okamura T, Ishizaka Y
    SMAD5 phosphorylation by ALK1 is modulated by the interaction of the spike protein of SARS-CoV-2 and angiotensin-converting enzyme 2.
    Antiviral Res. 2025;242:106261.
    PubMed         Abstract available

  4. YAO G, Shi X, Jiang H, Duan A, et al
    Design, synthesis, and biological evaluation of novel 6-aminoalkyl- and 7-heteroaryl substituted 7-deazapurine nucleoside analogs against SARS-CoV-2 Replication.
    Antiviral Res. 2025 Aug 1:106246. doi: 10.1016/j.antiviral.2025.106246.
    PubMed         Abstract available


    Drug Saf

  5. ORDONEZ-MENA JM, Kar D, Fan X, Ferreira F, et al
    Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.
    Drug Saf. 2025;48:1161-1175.
    PubMed         Abstract available


    J Infect Dis

  6. BERMEJO-JAMBRINA M, Zaderer V, Eder J, Diem G, et al
    The Role of Enoxaparin in Influenza Virus Infections and Its Therapeutic Implications.
    J Infect Dis. 2025 Sep 10:jiaf470. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  7. FAN W, Zeng X, Chen Y, Yu Q, et al
    A recombinant Marek's disease vaccine candidate provides complete protection against infectious bursal disease virus and H9 subtype avian influenza virus in chickens.
    J Virol. 2025 Sep 11:e0114925. doi: 10.1128/jvi.01149.
    PubMed         Abstract available

  8. LAN R, Yang J, Li J, Li H, et al
    Continuous evolution of Eurasian avian-like H1N1 swine influenza viruses with pdm/09-derived internal genes enhances pathogenicity in mice.
    J Virol. 2025 Sep 8:e0043025. doi: 10.1128/jvi.00430.
    PubMed         Abstract available

  9. NAKANO M, Miyamoto S, Ohnishi C, Nogami C, et al
    Influenza A virus circumvents the innate immune response through the sequestration of double-stranded RNA.
    J Virol. 2025 Sep 8:e0073725. doi: 10.1128/jvi.00737.
    PubMed         Abstract available


    JAMA

  10. LIU Z, Zhang L, Jiang M
    Influenza and COVID-19 Multicomponent Vaccine in Adults.
    JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12222.
    PubMed        

  11. RUDMAN SPERGEL AK, Callendret B, Kostanyan L
    Influenza and COVID-19 Multicomponent Vaccine in Adults-Reply.
    JAMA. 2025 Sep 8. doi: 10.1001/jama.2025.12225.
    PubMed        


    MMWR Morb Mortal Wkly Rep

  12. O'HALLORAN A, Habeck JW, Gilmer M, Threlkel R, et al
    Influenza-Associated Hospitalizations During a High Severity Season - Influenza Hospitalization Surveillance Network, United States, 2024-25 Influenza Season.
    MMWR Morb Mortal Wkly Rep. 2025;74:529-537.
    PubMed         Abstract available


    PLoS One

  13. MUHUNDHAKUMAR D, Clarke CS, Mills G, Ramsay AIG, et al
    Cohort profile: Design and methods for Project HERCULES (Healthcare Exemplar for Recovery from COVID 19 Using Linear Examination Systems): Multi-disciplinary implementation and evaluation of an asynchronous review clinic in NHS eye-care services.
    PLoS One. 2025;20:e0330863.
    PubMed         Abstract available

  14. CHOI J, Son G, Kim YS, Choi KH, et al
    Impact of depression, anxiety, and COVID-19 diagnosis on social isolation trajectories during the pandemic: A 3-year prospective cohort study.
    PLoS One. 2025;20:e0330118.
    PubMed         Abstract available

  15. RUDISILL C, Linvill K, Chupak A, Costa-Font J, et al
    Trust or money? Barriers to health and healthcare behavior during the COVID-19 pandemic.
    PLoS One. 2025;20:e0331600.
    PubMed         Abstract available

  16. GANGULY AP, Battaile JT, Harms M, Murray S, et al
    Charity coverage and decreased COVID-19 mortality among uninsured patients in Texas: A retrospective cohort study.
    PLoS One. 2025;20:e0330533.
    PubMed         Abstract available

  17. WILLEN SS, Mason KA, Wurtz HM, Karcher S, et al
    The Pandemic Journaling Project: A new dataset of first-person accounts of the COVID-19 pandemic.
    PLoS One. 2025;20:e0318397.
    PubMed         Abstract available

  18. LI Y, Sexton CL, Fitzpatrick A, Ruple A, et al
    An analysis of behavioral characteristics and enrollment year variability in 47,444 dogs entering the Dog Aging Project from 2020 to 2023.
    PLoS One. 2025;20:e0330257.
    PubMed         Abstract available

  19. DURANT EJ, Warton EM, Skarbinski J, Siqueiros MH, et al
    Predictors of health care utilization in patients with post-acute sequelae of COVID-19 (PASC).
    PLoS One. 2025;20:e0331370.
    PubMed         Abstract available

  20. GARBIN JRT, Leite FMC, Santos APBD, Dell'Antonio LS, et al
    Factors associated with prolonged hospitalizations for COVID-19 during the first three waves of the pandemic: Evidence from a Southeastern State of Brazil.
    PLoS One. 2025;20:e0332128.
    PubMed         Abstract available

  21. RABAGLIATI R, Benadof D, Thompson L, Garcia P, et al
    A prospective, multicenter study of invasive fungal disease caused by molds in children and adults in Chile.
    PLoS One. 2025;20:e0330426.
    PubMed         Abstract available

  22. KIM D, Kim T, Kim W, Youn H, et al
    When automation hits jobs: Entrepreneurship as an alternative career path.
    PLoS One. 2025;20:e0331244.
    PubMed         Abstract available

  23. ELSNER A, Mergl R, Allgaier AK, Hegerl U, et al
    Suicide rates in Germany in lockdown and non-lockdown phases during the COVID-19 pandemic in 2020/2021.
    PLoS One. 2025;20:e0331784.
    PubMed         Abstract available

  24. KIM J, Ewing CR, Larson A, Illapperuma-Wood C, et al
    Incidence of depression and anxiety in children and adolescents following COVID-19 infection.
    PLoS One. 2025;20:e0331984.
    PubMed         Abstract available

  25. MURPHY M, Friciu M, Roullin VG, Leclair G, et al
    Propofol emulsification in Intralipid and SMOFlipid: A promising alternative in response to future shortages.
    PLoS One. 2025;20:e0331651.
    PubMed         Abstract available

  26. XIA B, Pierce BS, Perrin PB
    Examining models of telemedicine use among U.S. physicians during the COVID-19 pandemic.
    PLoS One. 2025;20:e0331832.
    PubMed         Abstract available

  27. DELL'ANTONIO CSDS, Bierrenbach AL
    Epidemiological patterns of SARS-CoV-2 reinfections in Espirito Santo, Brazil: A population-based analysis using integrated surveillance and vaccination data.
    PLoS One. 2025;20:e0331771.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  28. LINOS E, Lasky-Fink J, Dorie V, Rothstein J, et al
    Interventions to bolster benefits take-up: Assessing intensity, framing, and targeting of government outreach.
    Proc Natl Acad Sci U S A. 2025;122:e2504747122.
    PubMed         Abstract available

  29. JIANG Z, Pan W, Chen Y, Zhou D, et al
    ApoD mediates age-associated increase in vulnerability to influenza virus infection.
    Proc Natl Acad Sci U S A. 2025;122:e2423973122.
    PubMed         Abstract available


    Vaccine

  30. HUANG YT, Tsou TP, Kuo SH, Huang YT, et al
    Assessment of influenza vaccine effectiveness among the elderly in Taiwan using population-based registry data for the 2023-2024 season.
    Vaccine. 2025;64:127690.
    PubMed         Abstract available

  31. BARBERIA LG, Seelaender ICR, Carvalho RJ, de Moraes JC, et al
    Caregivers' attitudes toward school-based vaccination programs: A comparison of COVID-19, HPV, influenza, and dengue vaccines in Brazil.
    Vaccine. 2025;64:127709.
    PubMed         Abstract available

  32. SANFTENBERG L, Kraeker L, Walter F, Tsiligianni I, et al
    Associations between common mental disorders and vaccination readiness against seasonal influenza and Covid-19 of chronically ill adult patients in primary care - a systematic review.
    Vaccine. 2025;64:127682.
    PubMed         Abstract available


    Virology

  33. SILVA MO, Daher IP, Oda Ibrahim CH, de Souza EE, et al
    Murine antibody 4B1D3 exhibits broad cross-reactivity and neutralizing activity against SARS-CoV-2 variants.
    Virology. 2025;611:110629.
    PubMed         Abstract available

  34. LU CY, Lai PY, Huang JM, Chang LY, et al
    Dual targeting of the Wnt and DNAJB6/MRJ regulatory loop as an anti-RSV strategy.
    Virology. 2025;611:110641.
    PubMed         Abstract available

  35. LUCINI PAIONI A, Donnici L, Nodari R, Longo Minnolo M, et al
    A rapid and robust luciferase-based reporter system to assess SARS-CoV-2 protease activity.
    Virology. 2025;611:110659.
    PubMed         Abstract available

  36. RAVINDRAN C, Mukherjee S
    Zebrafish as a model for SARS-CoV-2 infection, pathogenesis, transmission, and drug screening.
    Virology. 2025;611:110662.
    PubMed         Abstract available

  37. CHINNA P, Blumenthal MJ, Lambarey H, Jennings L, et al
    Assessment of gamma-herpesvirus infection dynamics in non-hospitalised people living with HIV during the COVID-19 pandemic in South Africa.
    Virology. 2025;611:110666.
    PubMed         Abstract available

  38. KIM KH, Hwang HS, Lee Y, Jung YJ, et al
    Interferon-gamma receptor signaling is critical for balanced immune activation and protection against influenza after vaccination.
    Virology. 2025;612:110674.
    PubMed         Abstract available

  39. QIAO Y, Tang M, Du M, Zhao C, et al
    H5N1 influenza virus-like particles based on BEVS induce robust functional antibodies and immune responses.
    Virology. 2025;612:110672.
    PubMed         Abstract available

  40. PAWAR SD, Tare DS, Keng SS, Walimbe AM, et al
    Tracing the possible origins of the clade 2.3.4.4b highly pathogenic avian influenza H5Nx viruses from India.
    Virology. 2025 Aug 29:110654. doi: 10.1016/j.virol.2025.110654.
    PubMed         Abstract available

Friday, September 12, 2025

Effective #treatment of advanced #Oropouche virus, Rift Valley fever virus, and Dabie #bandavirus #infections with 4'-fluorouridine

 


ABSTRACT

Oropouche virus (OROV), Rift Valley fever virus (RVFV), and Dabie bandavirus (DBV) are significant re-emerging and emerging human pathogens with major public health implications. Notably, the ongoing OROV disease epidemic spanning South America, Central America, and the Caribbean now exceeds 11,000 cases, including several fatalities and reports of neurological disease and congenital abnormalities associated with infection. Rift Valley fever outbreaks continue to plague sub-Saharan Africa, and DBV, the etiologic agent of severe fever with thrombocytopenia syndrome (SFTS), is expanding its reach throughout several Asian countries. No vaccines or approved therapies are available to prevent or treat these viral infections. Here, we report on the antiviral activity and protective efficacy of the ribonucleoside analog, 4′-fluorouridine (4′-FlU), against OROV, RVFV, and DBV in cell culture and murine models of infection and disease. In cell culture, the potency of 4′-FlU was in the low nanomolar (OROV) to low micromolar (RVFV and DBV) range. In vivo, prophylactic oral dosing of the compound was fully protective against all three viruses in their respective mouse infection models. Importantly, post-exposure and therapeutic interventions of advanced infections in mice also responded remarkably well to treatments. Our findings extend the broad-spectrum antiviral capacity of 4′-FlU and support the compound’s further development for treating severe bunyaviral infections.


IMPORTANCE

Re-emerging and emerging viral diseases, for which no approved vaccines or therapeutics exist, pose a significant public health threat in affected areas of the world. Antiviral drugs that are broadly active against multiple pathogenic viruses are much needed. Our findings demonstrating robust protection conferred by treatment with 4′-fluorouridine (4′-FlU) in viral infection models for Oropouche fever, Rift Valley fever, and severe fever with thrombocytopenia syndrome support the continuing development of this promising broad-spectrum antiviral drug candidate for the treatment of these notable viral diseases.

Source: mBio, https://journals.asm.org/doi/full/10.1128/mbio.01467-25?af=R

____

#Ebola virus’ hidden #target: virus #transmission to and infection of #skin

 


ABSTRACT

Ebola virus (EBOV), the causative agent of Ebola virus disease, remains one of the World Health Organization’s top 10 threats to global health. Infectious EBOV virions can be found on the surface of skin late in infection and may be transmitted to others through skin-to-skin contact. We investigate in vivo EBOV tropism and the kinetics of virus movement to and from the skin. Increasing viral loads were detected over time in the skin of EBOV-infected non-human primates and mice, with antigen detected in dermal stromal and immune cells. Epidermal cells within and surrounding hair follicles also harbored viral antigen, suggesting a novel mechanism of virus egress to the epidermal surface. During late infection, proinflammatory responses were elevated in infected visceral organs but minimal in the skin despite significant viral loads. We observed similar viral trafficking and cell tropism in the skin of mice intraperitoneally infected with a low containment EBOV model virus, rVSV/EBOV GP, allowing more detailed mechanistic studies. Sites of virus infection in the skin were patchy, with intense focal areas of infection surrounded by uninfected areas. To investigate virus entry into the body through skin, rVSV/EBOV GP was applied to the surface of gently abraded skin to remove the stratum corneum; epidermal keratinocytes were robustly infected with subsequent systemic viral dissemination observed in some mice. Optimal levels of infection within the skin required expression of the phosphatidylserine receptor, AXL. Collectively, our data demonstrate that skin serves as an important organ targeted by EBOV, facilitating virus entry into and egress from the body.

Source: Journal of Virology, https://journals.asm.org/doi/full/10.1128/jvi.01300-25?af=R

____

#USA, #Wastewater #Data for Avian #Influenza #H5 (#CDC, September 12 '25)

 


{Summary}

Time Period: August 31, 2025 - September 06, 2025

-- H5 Detection4 sites (0.9%)

-- No Detection418 sites (99.1%)

-- No samples in last week43 sites




(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/nwss/rv/wwd-h5.html

____

My New Space

Most Popular Posts